These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38593745)

  • 21. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.
    Humaidan P; Schertz J; Fischer R
    BMJ Open; 2015 Jul; 5(7):e008297. PubMed ID: 26141305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
    Carone D; Caropreso C; Vitti A; Chiappetta R
    J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of LH and FSH in ovarian function.
    Howles CM
    Mol Cell Endocrinol; 2000 Mar; 161(1-2):25-30. PubMed ID: 10773387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect.
    O'Dea L; O'Brien F; Currie K; Hemsey G
    Curr Med Res Opin; 2008 Oct; 24(10):2785-93. PubMed ID: 18727841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiles of cumulus cells obtained from women treated with recombinant human luteinizing hormone + recombinant human follicle-stimulating hormone or highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone alone.
    Gatta V; Tatone C; Ciriminna R; Vento M; Franchi S; d'Aurora M; Sperduti S; Cela V; Borzì P; Palermo R; Stuppia L; Artini PG
    Fertil Steril; 2013 Jun; 99(7):2000-8.e1. PubMed ID: 23472943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.
    Humaidan P; Bungum M; Bungum L; Yding Andersen C
    Reprod Biomed Online; 2004 Jun; 8(6):635-43. PubMed ID: 15169576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.
    Orvieto R; Venetis CA; Fatemi HM; D'Hooghe T; Fischer R; Koloda Y; Horton M; Grynberg M; Longobardi S; Esteves SC; Sunkara SK; Li Y; Alviggi C
    Front Endocrinol (Lausanne); 2021; 12():675670. PubMed ID: 34040586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.
    Wdowiak A; Bojar I
    Reprod Health; 2015 Dec; 12():113. PubMed ID: 26667662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
    Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
    Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).
    Grynberg M; Cedrin-Durnerin I; Raguideau F; Herquelot E; Luciani L; Porte F; Verpillat P; Helwig C; Schwarze JE; Paillet S; Castello-Bridoux C; D'Hooghe T; Benchaïb M
    Best Pract Res Clin Obstet Gynaecol; 2023 Jun; 88():102308. PubMed ID: 36707343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.
    Weiss NS; Kostova E; Nahuis M; Mol BWJ; van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD010290. PubMed ID: 30648738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human luteinizing hormone increases endometrial thickness in women undergoing assisted fertility treatments: a systematic review and meta-analysis.
    Mao R; Hou X; Feng X; Wang R; Fei X; Zhao J; Chen H; Cheng J
    Front Pharmacol; 2024; 15():1434625. PubMed ID: 39135787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation.
    Durnerin CI; Erb K; Fleming R; Hillier H; Hillier SG; Howles CM; Hugues JN; Lass A; Lyall H; Rasmussen P; Thong J; Traynor I; Westergaard L; Yates R;
    Hum Reprod; 2008 Feb; 23(2):421-6. PubMed ID: 18084048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
    Siristatidis CS; Gibreel A; Basios G; Maheshwari A; Bhattacharya S
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD006919. PubMed ID: 26558801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome.
    Bordewijk EM; Nahuis M; Costello MF; Van der Veen F; Tso LO; Mol BW; van Wely M
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD009090. PubMed ID: 28118681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve.
    Mignini Renzini M; Brigante C; Coticchio G; Dal Canto M; Caliari I; Comi R; De Ponti E; Fadini R
    J Assist Reprod Genet; 2017 Dec; 34(12):1645-1651. PubMed ID: 28871409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.